SeD PR Ebola Singapore eDevelopment Limited (Stock Code 40V)’s biomedical subsidiary confirms the LB2 drug efficacy against Ebola
SeD Initial Cancer Singapore eDevelopment Limited (Stock Code: 40V)’s Biomedical Subsidiary Completes Initial Cancer Research for New Universal Therapeutic Drug Platform
Global Biolife PR Linebacker Global BioLife, a Biomedical Subsidiary of Singapore eDevelopment Limited, Completes Cancer Research for New Universal Therapeutic Drug Platform
SeD PR Dr Moore Singapore eDevelopment Names Former USAssistant Surgeon General, Dr Roscoe Moore, as Senior Scientific Adviser to its Biomedical Arm
Confirms Repellency Singapore eDevelopment’s Biomedical Subsidiary Confirms 100% Repellency of 3F Mosquito Fragrance
SeD PressRelease BioLifeandQCandy Singapore Exchange-Listed Singapore eDevelopment’s U.S. Subsidiary Global BioLife Develops Breakthrough Modified Sugar
Sed 3F Collaboration Singapore eDevelopment Limited’s Biomedical Subsidiary forms Working Collaboration to Develop Functional Fragrances to Fight Mosquito-Borne Diseases
SeD Linebacker pdf Singapore eDevelopment Limited’s Bio-Medical Subsidiary Initiates Advanced Research of a New Universal Therapeutic Drug Platform, Led By Two-Time Nobel Prize Nominee